Literature DB >> 24641180

The compound BTB06584 is an IF1 -dependent selective inhibitor of the mitochondrial F1 Fo-ATPase.

Fabrice Ivanes1, Danilo Faccenda, Jemma Gatliff, Ahmed A Ahmed, Stefania Cocco, Carol Ho Ka Cheng, Emma Allan, Claire Russell, Michael R Duchen, Michelangelo Campanella.   

Abstract

BACKGROUND AND
PURPOSE: Ischaemia compromises mitochondrial respiration. Consequently, the mitochondrial F1 Fo-ATPsynthase reverses and acts as a proton-pumping ATPase, so maintaining the mitochondrial membrane potential (ΔΨm ), while accelerating ATP depletion and cell death. Here we have looked for a molecule that can selectively inhibit this activity without affecting ATP synthesis, preserve ATP and delay ischaemic cell death. EXPERIMENTAL APPROACH: We developed a chemoinformatic screen based on the structure of BMS199264, which is reported to selectively inhibit F1 Fo-ATPase activity and which is cardioprotective. Results suggested the molecule BTB06584 (hereafter referred to as BTB). Fluorescence microscopy was used to study its effects on ΔΨm and on the rate of ATP consumption following inhibition of respiration in several cell types. The effect of BTB on oxygen (O2 ) consumption was explored and protective potential determined using ischaemia/reperfusion assays. We also investigated a potential mechanism of action through its interaction with inhibitor protein of F1 subunit (IF1 ), the endogenous inhibitor of the F1 Fo-ATPase. KEY
RESULTS: BTB inhibited F1 Fo-ATPase activity with no effect on ΔΨm or O2 consumption. ATP consumption was decreased following inhibition of respiration, and ischaemic cell death was reduced. BTB efficiency was increased by IF1 overexpression and reduced by silencing the protein. In addition, BTB rescued defective haemoglobin synthesis in zebrafish pinotage (pnt) mutants in which expression of the Atpif1a gene is lost. CONCLUSIONS AND IMPLICATIONS: BTB may represent a valuable tool to selectively inhibit mitochondrial F1 Fo-ATPase activity without compromising ATP synthesis and to limit ischaemia-induced injury caused by reversal of the mitochondrial F1 Fo-ATPsynthase.
© 2014 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24641180      PMCID: PMC4241087          DOI: 10.1111/bph.12638

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  52 in total

1.  The structure of bovine IF(1), the regulatory subunit of mitochondrial F-ATPase.

Authors:  E Cabezón; M J Runswick; A G Leslie; J E Walker
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

2.  Imaging mitochondrial function in intact cells.

Authors:  Michael R Duchen; Alexander Surin; Jake Jacobson
Journal:  Methods Enzymol       Date:  2003       Impact factor: 1.600

3.  Guidelines for reporting experiments involving animals: the ARRIVE guidelines.

Authors:  J C McGrath; G B Drummond; E M McLachlan; C Kilkenny; C L Wainwright
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

4.  Forward operation of adenine nucleotide translocase during F0F1-ATPase reversal: critical role of matrix substrate-level phosphorylation.

Authors:  Christos Chinopoulos; Akos A Gerencser; Miklos Mandi; Katalin Mathe; Beata Töröcsik; Judit Doczi; Lilla Turiak; Gergely Kiss; Csaba Konràd; Szilvia Vajda; Viktoria Vereczki; Richard J Oh; Vera Adam-Vizi
Journal:  FASEB J       Date:  2010-03-05       Impact factor: 5.191

5.  Increased content of natural ATPase inhibitor in tumor mitochondria.

Authors:  K Luciaková; S Kuzela
Journal:  FEBS Lett       Date:  1984-11-05       Impact factor: 4.124

6.  Dimers of mitochondrial ATP synthase form the permeability transition pore.

Authors:  Valentina Giorgio; Sophia von Stockum; Manuela Antoniel; Astrid Fabbro; Federico Fogolari; Michael Forte; Gary D Glick; Valeria Petronilli; Mario Zoratti; Ildikó Szabó; Giovanna Lippe; Paolo Bernardi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

7.  Distribution of the ATPase inhibitor proteins of mitochondria in mammalian tissues including fibroblasts from a patient with Luft's disease.

Authors:  E W Yamada; N J Huzel
Journal:  Biochim Biophys Acta       Date:  1992-06-09

8.  Analogues of the nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist Ned-19 indicate two binding sites on the NAADP receptor.

Authors:  Daniel Rosen; Alexander M Lewis; Akiko Mizote; Justyn M Thomas; Parvinder K Aley; Sridhar R Vasudevan; Raman Parkesh; Antony Galione; Minoru Izumi; A Ganesan; Grant C Churchill
Journal:  J Biol Chem       Date:  2009-10-13       Impact factor: 5.157

9.  Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators.

Authors:  P G McGovern; J S Pankow; E Shahar; K M Doliszny; A R Folsom; H Blackburn; R V Luepker
Journal:  N Engl J Med       Date:  1996-04-04       Impact factor: 91.245

10.  IF1 limits the apoptotic-signalling cascade by preventing mitochondrial remodelling.

Authors:  D Faccenda; C H Tan; A Seraphim; M R Duchen; M Campanella
Journal:  Cell Death Differ       Date:  2013-01-25       Impact factor: 15.828

View more
  14 in total

Review 1.  New zebrafish models of neurodegeneration.

Authors:  Rebeca Martín-Jiménez; Michelangelo Campanella; Claire Russell
Journal:  Curr Neurol Neurosci Rep       Date:  2015-06       Impact factor: 5.081

2.  Mitochondrial pharmacology: energy, injury and beyond.

Authors:  S M Davidson; G D Lopaschuk; M Spedding; P M Beart
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 3.  Natural products and other inhibitors of F1FO ATP synthase.

Authors:  Bhargav A Patel; Terin L D'Amico; Brian S J Blagg
Journal:  Eur J Med Chem       Date:  2020-09-03       Impact factor: 6.514

4.  ATPase Inhibitory Factor-1 Disrupts Mitochondrial Ca2+ Handling and Promotes Pathological Cardiac Hypertrophy through CaMKIIδ.

Authors:  Mario G Pavez-Giani; Pablo I Sánchez-Aguilera; Nils Bomer; Shigeki Miyamoto; Harmen G Booij; Paula Giraldo; Silke U Oberdorf-Maass; Kirsten T Nijholt; Salva R Yurista; Hendrik Milting; Peter van der Meer; Rudolf A de Boer; Joan Heller Brown; Herman W H Sillje; B Daan Westenbrink
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

5.  Selective removal of deletion-bearing mitochondrial DNA in heteroplasmic Drosophila.

Authors:  Nikolay P Kandul; Ting Zhang; Bruce A Hay; Ming Guo
Journal:  Nat Commun       Date:  2016-11-14       Impact factor: 14.919

6.  Reverting the mode of action of the mitochondrial FOF1-ATPase by Legionella pneumophila preserves its replication niche.

Authors:  Lucien Platon; Mariatou Dramé; Pedro Escoll; Tobias Sahr; Silke Schmidt; Christophe Rusniok; Carmen Buchrieser
Journal:  Elife       Date:  2021-12-09       Impact factor: 8.140

7.  Underestimation of the Maximal Capacity of the Mitochondrial Electron Transport System in Oligomycin-Treated Cells.

Authors:  Juliana S Ruas; Edilene S Siqueira-Santos; Ignacio Amigo; Erika Rodrigues-Silva; Alicia J Kowaltowski; Roger F Castilho
Journal:  PLoS One       Date:  2016-03-07       Impact factor: 3.240

8.  Selective ATP hydrolysis inhibition in F1Fo ATP synthase enhances radiosensitivity in non-small-cell lung cancer cells (A549).

Authors:  Yupei Wang; Qinzheng Hou; Guoqing Xiao; Shifeng Yang; Cuixia Di; Jing Si; Rong Zhou; Yancheng Ye; Yanshan Zhang; Hong Zhang
Journal:  Oncotarget       Date:  2017-06-27

9.  Reduction of the ATPase inhibitory factor 1 (IF1) leads to visual impairment in vertebrates.

Authors:  Rebeca Martín-Jiménez; Danilo Faccenda; Emma Allen; Holly Beatrice Reichel; Laura Arcos; Caterina Ferraina; Daniela Strobbe; Claire Russell; Michelangelo Campanella
Journal:  Cell Death Dis       Date:  2018-06-04       Impact factor: 8.469

Review 10.  Targeting myocardial ischaemic injury in the absence of reperfusion.

Authors:  M V Basalay; D M Yellon; S M Davidson
Journal:  Basic Res Cardiol       Date:  2020-10-14       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.